For patients with HR+/HER2- advanced breast cancer whose disease progressed on one or more lines of treatment, several studies demonstrated a PFS benefit for CDK4/6 inhibitors plus endocrine therapy (Table 1). Here, ERBB2 is linked to breast carcinoma.